Valeant Pharmaceuticals (VRX) Chairman/CEO Buys 49.9K Shares
More News related to VRX
- Valeant Pharmaceuticals (VRX) and GlaxoSmithKline Enter Collaboration for Retigabine
- Valeant Pharmaceuticals and GlaxoSmithKline Announce Worldwide Collaboration Agreement for Retigabine
- Matrix USA Rating Changes 8/25
- Valeant Pharmaceuticals to Present at UBS Global Life Sciences Conference
- JANA Partners 13F Shows New Stakes in Genentech (DNA), Sears (SHLD), Washington Mutual (WM); Adds to Positions in AK Steel (AKS), Focus Media (FMCN), Transocean (RIG); Sells Out of Apple (AAPL), Lehma
Valeant Pharmaceuticals (NYSE: VRX) Chairman and CEO, Michael Pearson, purchased 49,900 shares on 6/12 at a price of $16.70, bringing his stake to 395,811 shares.
Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products.
Related Categories
Insider TradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
